<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02328209</url>
  </required_header>
  <id_info>
    <org_study_id>UMIN000014056</org_study_id>
    <nct_id>NCT02328209</nct_id>
  </id_info>
  <brief_title>Evaluation of the Simplified Treat And Extend Regimen Using Ranibizumab in Exudative Age Related Macular Degeneration</brief_title>
  <official_title>Evaluation of the Efficacy and Continuance Rate of Treatment in Simplified Treat And Extend Regimen Using Ranibizumab in Exudative Age Related Macular Degeneration</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mie University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mie University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Recently studies have shown that intravitreal injection of ranibizumab is effective for age
      related macular degeneration. However there are problems about injection regimen of
      maintenance phase. We plan to perform new simplified treat and extend regimen using
      ranibizumab.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of the present study is to evaluate the simplified treat and extend regimen using
      ranibizumab in eyes with wet age related macular degeneration about best-corrected visual
      acuity, central retinal thickness, the disappearance rate of the morphological change and
      treatment continuous rate.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>June 2014</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>A change from baselines best corrected visual acuity at 24 months</measure>
    <time_frame>24 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>A drop-out rate of the 3 and 12 months</measure>
    <time_frame>3 and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>A treatment continuance rate until 24 months</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>A change of best corrected visual acuity at 12 months</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>A change from baselines central retinal thickness measured by spectral domain optical coherence tomography at 12 and 24 months</measure>
    <time_frame>12 and 24 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Exudative Age-related Macular Degeneration</condition>
  <arm_group>
    <arm_group_label>ranibizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ranibizumab</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ranibizumab</intervention_name>
    <description>0.5mg/0.05ml, intravitreal injection, frequency: each 8 or 12 weeks</description>
    <arm_group_label>ranibizumab</arm_group_label>
    <other_name>Lucentis</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. ability to provide written informed consent for this study

          2. age&gt;=50years old

          3. intravitreal injection of ranibizumab as a first therapy for neovascular age-related
             macular degeneration (typical age-related macular degeneration and PCV)

          4. best corrected visual acuity&gt;=0.05 -

        Exclusion Criteria:

          1. past intravitreal anti-vascular endothelial growth factor therapy in the study eye

          2. past intravitreal or subtenon injection of steroid therapy in the study eye

          3. past vitrectomy therapy in the study eye

          4. infection or suspicion of infection in eyes or periocular region

          5. severe intraocular inflammation in eyes

          6. past allergic reaction for ranibizumab

          7. past allergic reaction for fluorescein, indocyanine green or iodine

          8. pregnancy (positive pregnancy test) or lactating women

          9. other conditions that the investigator believed would pose a significant hazard to the
             subject if investigational therapy were initiated.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mineo Kondo</last_name>
    <role>Study Chair</role>
    <affiliation>Mie University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mie University Graduate School of Medicine</name>
      <address>
        <city>Tsu</city>
        <zip>5148507</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mineo Kondo</last_name>
      <phone>+81592321111</phone>
      <phone_ext>6461</phone_ext>
      <email>ganka@clin.medic.mie-u.ac.jp</email>
    </contact>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <results_reference>
    <citation>Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, Sy JP, Schneider S; ANCHOR Study Group. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006 Oct 5;355(14):1432-44.</citation>
    <PMID>17021319</PMID>
  </results_reference>
  <results_reference>
    <citation>Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, Kim RY; MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006 Oct 5;355(14):1419-31.</citation>
    <PMID>17021318</PMID>
  </results_reference>
  <verification_date>December 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 19, 2014</study_first_submitted>
  <study_first_submitted_qc>December 26, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 31, 2014</study_first_posted>
  <last_update_submitted>December 26, 2014</last_update_submitted>
  <last_update_submitted_qc>December 26, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 31, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mie University</investigator_affiliation>
    <investigator_full_name>Mineo Kondo</investigator_full_name>
    <investigator_title>Mie University Graduate School of Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
    <mesh_term>Wet Macular Degeneration</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ranibizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

